Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 1
2002 1
2004 2
2005 1
2008 3
2009 3
2010 3
2011 1
2012 2
2013 1
2014 3
2015 3
2016 3
2017 8
2018 1
2019 4
2020 5
2021 3
2022 8
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. Shepherd JH, et al. Among authors: collyar d. J Clin Oncol. 2022 Apr 20;40(12):1323-1334. doi: 10.1200/JCO.21.01506. Epub 2022 Jan 19. J Clin Oncol. 2022. PMID: 35044810 Free PMC article. Clinical Trial.
Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK, Almekinders MM, Mulder C, Bhattacharjee P, Collyar D, Thompson AM, Jonkers J, Lips EH, van Rheenen J, Hwang ES, Nik-Zainal S, Navin NE, Wesseling J; Grand Challenge PRECISION Consortium. Casasent AK, et al. Among authors: collyar d. Nat Rev Cancer. 2022 Dec;22(12):663-678. doi: 10.1038/s41568-022-00512-y. Epub 2022 Oct 19. Nat Rev Cancer. 2022. PMID: 36261705 Review.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. Among authors: collyar d. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.
The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.
Evans SR, Patel R, Hamasaki T, Howard-Anderson J, Kinamon T, King HA, Collyar D, Cross HR, Chambers HF, Fowler VG, Boucher HW; Antibacterial Resistance Leadership Group. Evans SR, et al. Among authors: collyar d. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S321-S330. doi: 10.1093/cid/ciad538. Clin Infect Dis. 2023. PMID: 37843122
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM. Anagnostou V, et al. Among authors: collyar d. Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065. Clin Cancer Res. 2017. PMID: 28864724 Free PMC article.
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
Schmitz RSJM, van den Belt-Dusebout AW, Clements K, Ren Y, Cresta C, Timbres J, Liu YH, Byng D, Lynch T, Menegaz BA, Collyar D, Hyslop T, Thomas S, Love JK, Schaapveld M, Bhattacharjee P, Ryser MD, Sawyer E, Hwang ES, Thompson A, Wesseling J, Lips EH, Schmidt MK; Grand Challenge PRECISION consortium. Schmitz RSJM, et al. Among authors: collyar d. BMJ. 2023 Oct 30;383:e076022. doi: 10.1136/bmj-2023-076022. BMJ. 2023. PMID: 37903527 Free PMC article.
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, Casasent AK, Clements K, Davies HR, Fu L, Grigoriadis A, Hardman TM, King LM, Krete M, Kristel P, de Maaker M, Maley CC, Marks JR, Menegaz BA, Mulder L, Nieboer F, Nowinski S, Pinder S, Quist J, Salinas-Souza C, Schaapveld M, Schmidt MK, Shaaban AM, Shami R, Sridharan M, Zhang J, Stobart H, Collyar D, Nik-Zainal S, Wessels LFA, Hwang ES, Navin NE, Futreal PA; Grand Challenge PRECISION consortium; Thompson AM, Wesseling J, Sawyer EJ. Lips EH, et al. Among authors: collyar d. Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9. Nat Genet. 2022. PMID: 35681052 Free PMC article.
The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. Mehnert JM, et al. Among authors: collyar d. Clin Cancer Res. 2017 Sep 1;23(17):4970-4979. doi: 10.1158/1078-0432.CCR-16-3063. Clin Cancer Res. 2017. PMID: 28864725 Free PMC article.
61 results